Risk for Cardiovascular Disease Greater for Childhood Cancer Survivors
Exposure to ≥250 mg/m² doxorubicin-equivalent anthracycline chemo tied to risk for CVD, heart failure.
Pediatric Cancer News
PEDIATRIC CANCER ADVISOR
Pediatric Cancer News
Bone Health Management Key in Childhood Cancer Survivors
Working group reviewed bone complications to form recommendations for management of bone health.
Global Burden of Childhood Cancers Examined
Burden of childhood cancers disproportionately affects populations in resource-limited settings.
LIBRETTO-121: A Phase 1/2 Trial Investigating LOXO-292 in Pediatric Patients With Advanced Solid or Primary CNS Tumors
A primary outcome measure for phase 1 of the trial is determining the safety of oral LOXO-292.
Phase 1/2 Study of Durvalumab and Tremelimumab in Pediatric Cancer
After phase 1, the study will expand in a second phase to test the efficacy of these drugs at the determine dosage.
Overall Cancer Survival Rates Up Among Adolescents, Young Adults
Cancer survival has improved among adolescents and young adults (AYA), but survival disparities are reported.
Higher Risk for Cancer, Mortality Seen With Pediatric-Onset IBD
Individuals with pediatric-onset inflammatory bowel disease (pIBD) have an increased risk for cancer and mortality.
Less Postoperative Chemotherapy for Pediatric Hepatoblastoma Has No Effect on Disease Control
Fewer chemotherapy cycles could decrease long-term morbidity for certain patients.
Potential Unintended Consequences of the “Right to Try” Act on the Delivery of Palliative Care to Children With Cancer
Will “cure-seeking behavior” for terminally ill children with cancer interfere with the integrated delivery of palliative care?
“Real-World” Hospitalization Data on Patients Receiving CAR-T Cell Therapy
An investigation of a large performance improvement clinical database revealed that most individuals receiving CAR-T have diagnoses of ALL or large B-cell lymphoma.
The Price Is Right for CAR-T in Pediatric Patients, Analysis Concludes
For children with relapsed or refractory B-cell acute lymphoblastic leukemia, tisagenlecleucel was deemed cost-effective, yet long-term outcomes are still uncertain.
Vigorous Exercise Improved Life Expectancy for Adult Survivors of Childhood Cancers
Researchers report on a retrospective cohort analysis that evaluated the long-term effects of vigorous exercise for survivors of childhood cancer.
Relative Survival for AYAs Comparable to General Population After 7 Years
Survivorship plans for adolescent and young adult survivors need to consider the relative long-term survival for AYAs with certain cancers. Those with certain cancers may have excess long-term mortality.
Socioeconomic Status May Preclude Elderly Patients From Receiving Pancreatic Cancer Treatment
The adjusted OR for receiving any treatment was 0.33 among patients living in an area where at least 20% of the population was below the poverty line.
Pediatric Patients Hospitalized for Pneumonia May Have Elevated Cancer Risk
Short-term incidence of leukemia, lymphoma, and brain cancer may be higher in children who were hospitalized with pneumonia.
Ontuxizumab May Be Safe for Pediatric Patients With Relapsed/Refractory Solid Tumors
No dose-limiting toxicities were observed among the 6 patients who received ontuxizumab 4 mg/kg and 6 patients who received 8 mg/kg.
Pediatric Acute Promyelocytic Leukemia: Arsenic Trioxide Consolidation May Improve Outcomes
Consolidation with ATO allows a decrease in the cumulative dose of anthracycline while maintaining survival rates and a low risk of relapse among pediatric patients with APL.
Phase 2 Study Targeting Specific Genes in Pediatric Solid Tumors
The NCI and COG announced open enrollment for a study designed to evaluate the effectiveness of genetically matched targeted therapies for pediatric patients with cancer.
Lower-dose ATLG Effective for Preventing Pediatric GVHD
Pediatric patients with hematological malignancies who receive HSCT from an unrelated donor have greater benefit from a 15 mg/kg vs a 30 mg/kg dose of ATLG.
Burtomab Granted Breakthrough Therapy Designation for Metastatic Neuroblastoma
The US Food and Drug Administration granted Breakthrough Therapy Designation to burtomab for relapsed/refractory metastatic neuroblastoma.
Want to read more?
Please login or register first to view this content.
